{"id":"tramadol-pr-oral","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-15","effect":"Headache"},{"rate":"5-15","effect":"Somnolence"},{"rate":"5-10","effect":"Vomiting"},{"rate":"<1","effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL1237065","moleculeType":"Small molecule","molecularWeight":"299.84"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tramadol works through dual mechanisms: it acts as a weak mu opioid receptor agonist to reduce pain signaling, and simultaneously inhibits the reuptake of norepinephrine and serotonin in the central nervous system, enhancing descending pain inhibitory pathways. The PR (prolonged-release) formulation provides extended drug delivery over 24 hours, allowing for once or twice-daily dosing for chronic pain management.","oneSentence":"Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:41.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to moderately severe chronic pain"}]},"trialDetails":[{"nctId":"NCT02528253","phase":"PHASE3","title":"A Phase 3 Study of Tanezumab for Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-18","conditions":"Low Back Pain","enrollment":1832},{"nctId":"NCT03902340","phase":"NA","title":"Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.","status":"UNKNOWN","sponsor":"Sublimed","startDate":"2018-12-19","conditions":"Knee Osteoarthritis","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tramadol PR oral","genericName":"Tramadol PR oral","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief. Used for Moderate to moderately severe chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}